B7-H3 is a New Cancer-specific Endothelial Marker in Clear Cell Renal Cell Carcinoma

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2013 Nov 23

PMID 24265557

Citations 42

Authors

Xiaojian Qin

Hailiang Zhang

Dingwei Ye

Bo Dai

Yao Zhu

Guohai Shi

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to validate B7-H3 as a new cancer-specific endothelial marker in clear cell renal cell carcinoma.

Methods: B7-H3 expression patterns were compared between cancer and paired adjacent normal renal parenchyma by immunohistochemistry in paraffin-embedded specimens from 200 consecutive patients with clear cell renal cell carcinoma from January to December 2010. Four corpus luteum specimens were used as physiologic angiogenesis controls. B7-H3 messenger (m)RNA levels representing circulating endothelial cells were analyzed in 24 peripheral blood samples using real-time polymerase chain reaction. Collection and processing of tissue and peripheral blood samples was performed in compliance with the Declaration of Helsinki.

Results: Cancer cell-specific expression of B7-H3 was detected in 19% of clear cell renal cell carcinoma specimens, and tumor vasculature B7-H3 expression was confirmed in 98% (196) of cases. A diffuse pattern of vascular B7-H3 expression was associated with multiple adverse clinical and pathologic features (P<0.001). B7-H3 expression was not detected in paired adjacent normal renal parenchyma or vessels, or in luteal blood vessels. The B7-H3 mRNA level of circulating endothelial cells in peripheral blood was significantly higher in metastatic clear cell renal cell carcinoma (P<0.001).

Conclusion: This pilot study indicates that B7-H3 is a cancer-specific endothelial marker of potential importance for the development of tumor-specific, vascular-targeted therapies, and is a prognostic marker in clear cell renal cell carcinoma.

Citing Articles

A Pan-Cancer Analysis of the Oncogenic Role of CD276 in Human Tumors.

Liu L, Yao Z, Liu Y, Li Y, Ding Y, Hu J Genes (Basel). 2025; 15(12.

PMID: 39766794 PMC: 11675885. DOI: 10.3390/genes15121527.

Turning attention to tumor-host interface and focus on the peritumoral heterogeneity of glioblastoma.

Wang F, Dong J, Xu Y, Jin J, Xu Y, Yan X Nat Commun. 2024; 15(1):10885.

PMID: 39738017 PMC: 11685534. DOI: 10.1038/s41467-024-55243-5.

Impact of B7-H3 expression on metastasis, immune exhaustion and JAK/STAT and PI3K/AKT pathways in clear cell renal cell carcinoma.

Emaldi M, Rey-Iborra E, Marin A, Mosteiro L, Lecumberri D, Oyjord T Oncoimmunology. 2024; 13(1):2419686.

PMID: 39621555 PMC: 11540085. DOI: 10.1080/2162402X.2024.2419686.

CD276 as a promising diagnostic and prognostic biomarker for bladder cancer through bioinformatics and clinical research.

Zhou Q, Xu J, Chen X, Ouyang J, Mao C, Zhang Z Front Oncol. 2024; 14:1445526.

PMID: 39319055 PMC: 11419956. DOI: 10.3389/fonc.2024.1445526.

New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3.

Koumprentziotis I, Theocharopoulos C, Foteinou D, Angeli E, Anastasopoulou A, Gogas H Vaccines (Basel). 2024; 12(1).

PMID: 38250867 PMC: 10820813. DOI: 10.3390/vaccines12010054.

References

St Croix B, Rago C, Velculescu V, Traverso G, Romans K, Montgomery E . Genes expressed in human tumor endothelium. Science. 2000; 289(5482):1197-202. DOI: 10.1126/science.289.5482.1197. View

Chapoval A, Ni J, Lau J, Wilcox R, Flies D, Liu D . B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001; 2(3):269-74. DOI: 10.1038/85339. View

Nanda A, Carson-Walter E, Seaman S, Barber T, Stampfl J, Singh S . TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res. 2004; 64(3):817-20. DOI: 10.1158/0008-5472.can-03-2408. View

Furstenberger G, von Moos R, Senn H, Boneberg E . Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis. Br J Cancer. 2005; 93(7):793-8. PMC: 2361631. DOI: 10.1038/sj.bjc.6602782. View

Bertolini F, Shaked Y, Mancuso P, Kerbel R . The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer. 2006; 6(11):835-45. DOI: 10.1038/nrc1971. View

Steinberger P, Majdic O, Derdak S, Pfistershammer K, Kirchberger S, Klauser C . Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol. 2004; 172(4):2352-9. DOI: 10.4049/jimmunol.172.4.2352. View

Crispen P, Sheinin Y, Roth T, Lohse C, Kuntz S, Frigola X . Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008; 14(16):5150-7. PMC: 2789387. DOI: 10.1158/1078-0432.CCR-08-0536. View

Pusztaszeri M, Seelentag W, Bosman F . Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem. 2005; 54(4):385-95. DOI: 10.1369/jhc.4A6514.2005. View

Seaman S, Stevens J, Yang M, Logsdon D, Graff-Cherry C, St Croix B . Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 2007; 11(6):539-54. PMC: 2039723. DOI: 10.1016/j.ccr.2007.04.017. View

10.

Loos M, Hedderich D, Friess H, Kleeff J . B7-h3 and its role in antitumor immunity. Clin Dev Immunol. 2010; 2010:683875. PMC: 2993024. DOI: 10.1155/2010/683875. View

11.

Loo D, Alderson R, Chen F, Huang L, Zhang W, Gorlatov S . Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012; 18(14):3834-45. DOI: 10.1158/1078-0432.CCR-12-0715. View

12.

Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F . Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood. 2001; 97(11):3658-61. DOI: 10.1182/blood.v97.11.3658. View

13.

Hioki T, Sugimura Y . [Detection of circulating cancer cells by nested reverse transcription-polymerase chain reaction of cytokeratin-19 in patients with renal cell carcinoma]. Hinyokika Kiyo. 1999; 45(8):577-81. View

14.

Lainakis G, Bamias A . Targeting angiogenesis in renal cell carcinoma. Curr Cancer Drug Targets. 2008; 8(5):349-58. DOI: 10.2174/156800908785133132. View

15.

Chaudhary A, Hilton M, Seaman S, Haines D, Stevenson S, Lemotte P . TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell. 2012; 21(2):212-26. PMC: 3289547. DOI: 10.1016/j.ccr.2012.01.004. View